Background: Current end-of-life hospital care can be of poor quality and high cost. High volume and/or specialist care, and standardized care with clinical practice guidelines, has improved outcomes and costs in other areas of cancer care.
INTRODUCTION E
N D-OF-LIFE CARE SUFFERS from lack of quality care and high cost. The Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments (SUPPORT) showed that half of all hospitalized conscious patients died with unrelieved pain. 1 The other serious problem is the cost, with one eighth of Medicare total expenditures going to patients in their last month of life. 2, 3 Hospice saves an insignificant amount of cost at the end of life. 4, 5 In SUPPORT, one third of fam-ilies were bankrupted by end-of-life care; the poorest were most financially stressed and being poor was associated with fewer choices in endof-life care. 6 Medical expenditures are again increasing at near double-digit annual rates 7 so the situation is likely to worsen.
There is an important strong relationship between high volume and specialization of care, and the quality of care. 8, 9 Clinical practice guidelines and standardized care can often improve care and make it less expensive. 10 We started an inpatient Palliative Care Unit (PCU) staffed by a high-volume experienced specialist team 11 using standard protocols to improve end-of-life care. This study addresses the cost of care for patients who died in our hospital during the first 6 months of PCU operation.
METHODS

The Thomas Palliative Care Unit
The Thomas PCU opened in May 2000 as a hospital-based 11-bed inpatient unit, geographically separate from oncology, with its own nursing and administrative staff. We developed palliative care guidelines for the most common conditions such as pain, dyspnea, delirium, etc., available on request. In some cases, these were modeled after the American Society of Clinical Oncology Symptom Management Curriculum. 12 For the physician, writing "Use palliative care unit standing orders," could activate this order set. While cost was not a primary consideration in these guidelines, we had a strong consciousness of cost because our institution provides 60% of the indigent care in the state of Virginia, and one of the explicit goals of the PCU was to serve the medically underserved.
Referrals to the unit come from all over the hospital including the intensive care units (ICU) and general medicine, gynecology, neurology, and surgery. In addition, we signed contracts with local hospice providers to hospitalize those with hospice benefits. To avoid duplication of services, we did not start an outpatient hospice program.
The high-volume specialist care team
Two members of the team (P.C. and T.S.) provided most of the care during this phase of operation, with assistance from other faculty oncologists, pulmonologists, and infectious disease experts with an interest in palliative care. Both have had extensive experience in palliative care.
Financial analysis of patients hospitalized on the PCU
The objective of this study was to measure the impact of the PCU on cost of care. We compared daily charges and costs of the days prior to PCU transfer to the stay in the PCU. Charges and costs per day are compared for ICUs, Intermediate Care Units ("step-down" or telemetry units), all non-PCU units, and routine units to the PCU.
We then performed a case-control study by matching PCU patients by diagnosis and age to contemporary patients who died outside the PCU, cared for by other medical or surgical teams. We found 38 cases and controls that had the same diagnosis and were within 5 years of age in the May to December 2000 time period. All the available control case charts or electronic records were reviewed by one study member (T.S.) to ensure that the clinical characteristics of the case, expected outcomes, and causes of death were similar.
Charges, costs, and demographic/clinical data were captured by the Massey Cancer Center Database, which records information on all cancer patients in order to maintain quality and track health care outcomes. All charges are recorded on a standard charge master code. Costs are estimated using detailed internal cost accounting. Means 6 standard deviations are shown. All t tests are two-tailed. The study was approved by the Institutional Review Board, with waiver for informed consent (all the cases and controls were deceased, and the only information collected was done in the routine care of patients).
Quality of care was not directly measured, because there are no proven outcome indicators for end-of-life care. We assessed the following process measures: recording of Visual Analogue Scale (VAS) pain scores, visitation by a chaplain, and discussion of hospice referral or hospice enrollment. Goal of therapy was not directly assessable, because few charts documented any sort of goal.
RESULTS
In the May to December period, 237 patients were admitted to the PCU. Approximately half had cancer followed by vascular events, acquired immune deficiency syndrome (AIDS), and organ failure, as shown in Table 1 . Of the PCU patients, 56% were African American, the same percentage as the rest of the hospital.
When the days prior to the PCU transfer were compared to the average PCU stay, for the 123 patients who had both PCU and non-PCU stays, charges and costs per day were reduced by 66% overall and 74% in "other" (e.g. medications, diagnostics, etc.; p , 0.0001 for both charges and costs, comparing each type of unit to the PCU), as shown in Table 2 . In addition, the variation in costs was reduced significantly. We explored the costs for all patients before and after consultation and transfer. In general, the consultation was done 8-12 hours before actual transfer. We discussed goals of treatment with the patient and family, and carefully scrutinized each order and removed those items not directly needed for comfort. We did not automatically stop antibiotics, fluids, etc., unless the family or patient requested or agreed; over time, many chose to forego such interventions. Figure 1 shows that charges and costs decreased substantially around the time of the consultation (typically 8-12 hours before the transfer time, which is shown as the vertical line).
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We next performed a case-control study to compensate for the difference in treatment goals that might have existed between PCU and non-PCU patients. We compared the charges and costs for the hospitalization for patients who died in the PCU to those who died in the hospital outside the PCU during the same period. We found 57 patients who matched by diagnosis, and 38 who matched for diagnosis and age within 5 years as shown in Table 3 . The patient groups were nearly identical in age, gender, diagnosis, and type of treatments given.
Charges were reduced from $5,304 6 5,850 to $2,172 6 2,250 (p 5 0.005), direct costs from $1,441 6 1,438 to $632 6 690 (p 5 0.004), and total costs from $2,538 6 2,918 to $1,095 6 1,153 (p 5 0.009) as shown in Table 4 . These are conservative estimates, because we included the non-PCU (more costly) segment of the stay in the PCU patients, which raised the average charges and costs of the PCU cohort.
Although we have not formally measured it, patient and family satisfaction remains high. We regularly receive thank you notes from patients and families, had an outstanding response to our first annual memorial service, and have been recognized as one of the innovators in palliative care. 11 We studied some process indicators for care of the 38 patients compared to their controls. stance, all PCU patients had pain scores measured, compared to two thirds of non-PCU patients, and all PCU patients had chaplain visits offered compared to one third of the non-PCU patients. In all but one of the control cases, death was predictable from the admission history and physical, yet only one had a hospice discussion, and none had enrollment in hospice (the patient died while waiting for a hospice bed at a local Veterans' Administration Medical Center). There were substantial opportunities to reduce the care in nearly every case, such as stopping oxygen unless dyspnea was present (minimum $125 charge per day); stopping megestrol acetate ($12 per day for 800-mg suspension), omeprazole ($3 or more per day) or other proton pump inhibitors, intravenous fluids, etc.
DISCUSSION
Appropriate care of medically complex terminally ill patients in a high-volume, specialized unit appears to significantly lower cost. Our daily charges and costs of dying patients decreased substantially by the use of standardized procedures delivered by specialists in a high-volume setting.
Others have found similar results with attempts to improve end-of-life care, although no center has reported results for in-hospital end-oflife care. A randomized clinical trial of a nurse coordinator for terminally ill patients in England did not change disease outcomes but total costs were reduced from £8814 to £4414 for cost savings of 41%. 13, 14 The savings came from decreased hospital days and a shift to outpatient care.
The City of Hope National Medical Center designed a three-part program to prevent unnecessary hospitalizations for pain control. Pain admissions decreased from 4.4% to 3.0% with a cost savings of $1,666 per day that equaled $2,719,245. 15 It is important to change the type of care, or choose the type of care to which this model is applied, or costs may simply be shifted from one source to another with only minor net savings. [16] [17] [18] PALLIATIVE CARE UNIT COSTS 703 Bruera 19 implemented a Regional Palliative Care Program to increase access of terminally ill patients to palliative care, and to decrease in-hospital deaths and lengthy admissions. Deaths in acute care facilities declined from 84%-55%; the number of dying patients receiving palliative care increased from 23%-71%, and cost savings were estimated at $1,700,000 Canadian. Our group developed a the Rural Cancer Outreach Program (RCOP) between two rural hospitals and the Medical College of Virginia's (MCV) Massey Cancer Center to bring state-of-the-art cancer care to medically undeserved rural patients. 20 Improvements were noted in pain control as measured by morphine use, which increased 700% the first 2 years and has been sustained. The cost for each RCOP patient admitted to MCV decreased by more than 40%, compared to only a 2% decrease for all other cancer patients consistent with increased coordination among providers. 21 There are some obvious shortcomings to this study. First, it was not a randomized controlled trial because it was not ethical to randomize to "best care by experts using state of the art standardized algorithms in a dedicated unit" to regular hospital care. The rapid acceptance of the unit now prevents an in-hospital randomization. Second, at least some of the savings can be attributed to the change in goals of care. That is, once people are clearly identified as dying, much of the costly intervention is stopped. However, in our consultation we often found evidence of intensive and expensive interventions (multiple methods of pain control, expensive antibiotics, total parenteral nutrition or tube feedings, oxygen use, planned diagnostic tests such as magnetic resonance or computer tomography scans, etc.) when it was quite clear that the patient and family were accepting death. Those patients who were not transferred generally kept these interventions. The most likely reason is that the attending medical care team did not know how to change care patterns. A curriculum to teach the skills of defining goals of care and switching from active treatment to palliative care is now available. 22 Last, the costs in the rest of the hospital could be inflated, but our costs are midrange in our insurance market.
We addressed some of these issues with the case-control study of patients who died without the benefit of the PCU team-and showed that costs were reduced by nearly 60%. We cannot be sure that the patients in the case-control group were completely similar because this was not a randomized trial. However, we did review the charts and found no difference in demographics, disease status, predictability of death, type of intervention, etc. In addition, our PCU group for this study included the more expensive non-PCU portion of their costs, before transfer and standardization of care. Had we excluded the care and cost prior to PCU stay, the differences between the two groups would be even more striking.
In summary, appropriate standardized care of medically complex terminally ill patients in a high-volume, specialized unit appears to lower cost significantly. This is supported by other studies of coordinated care, regional programs, and standardization of palliative and cancer care. If these findings are confirmed by other studies, particularly randomized controlled trials, the cost savings would be significant.
